10 ResMed Analyst Ratings, Earnings, Dividends and Insider Trades | $RMD | NYSE:RMD | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact ResMed Company Profile (NYSE:RMD) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for ResMed (NYSE:RMD) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 10 Hold Rating(s), 4 Buy Rating(s)Consensus Rating:Hold (Score: 2.29)Consensus Price Target: $47.00 (5.55% upside) Analysts' Ratings History for ResMed (NYSE:RMD) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/10/2014ZacksReiterated RatingNeutral -> Neutral$46.00View 2/28/2014MacquarieUpgradeNeutral -> OutperformView 2/28/2014JPMorgan Chase & Co.DowngradeOverweight -> NeutralView 1/28/2014Morgan StanleyDowngradeOverweight -> Equal WeightView 1/27/2014CIMBDowngradeOutperform -> HoldView 1/24/2014Canaccord GenuityLower Price TargetHold$49.00 -> $43.00View 1/24/2014William BlairDowngradeOutperform -> Market PerformView 1/24/2014Jefferies GroupLower Price Target$46.00 -> $40.00View 1/24/2014BMO Capital MarketsLower Price Target$47.00 -> $43.00View 1/17/2014MacquarieDowngradeOutperform -> NeutralView 11/4/2013ZacksDowngradeOutperform -> Neutral$59.40View 10/25/2013Jefferies GroupBoost Price TargetHold$40.00 -> $46.00View 10/25/2013UBS AGUpgradeNeutral -> BuyView 10/25/2013Deutsche BankDowngradeBuy -> Hold$58.00 -> $54.00View 10/9/2013Piper JaffrayBoost Price Target$54.00 -> $59.00View 10/8/2013Northland Capital PartnersInitiated CoverageMarket Perform$44.00View 10/7/2013Northland SecuritiesInitiated CoverageMarket PerformView 10/4/2013ZacksUpgradeNeutral -> Outperform$55.40View 10/2/2013UBS AGDowngradeBuy -> Neutral$50.50View 9/23/2013Goldman SachsUpgradeBuyView 8/26/2013Bank of AmericaUpgradeNeutral -> BuyView 8/26/2013Bank of AmericaUpgradeNeutral -> BuyView 8/12/2013ZacksDowngradeOutperform -> Neutral$52.20View 8/5/2013Canaccord GenuityBoost Price TargetHold$48.00 -> $49.00View 8/2/2013Deutsche BankUpgradeHold -> BuyGBX 46 -> GBX 54View 7/30/2013UBS AGUpgradeNeutral -> BuyView 7/19/2013Jefferies GroupLower Price TargetHold$42.00 -> $40.00View 7/17/2013Goldman SachsDowngradeBuy -> NeutralView 7/17/2013MacquarieUpgradeNeutral -> OutperformView 7/16/2013Needham & CompanyInitiated CoverageHoldView 7/8/2013ZacksUpgradeNeutral -> Outperform$52.20View 6/27/2013Deutsche BankReiterated RatingHold$45.00 -> $46.00View 4/26/2013Goldman SachsUpgradeBuy -> Conviction-BuyView 3/7/2013MizuhoLower Price TargetNeutral$45.00 -> $42.00View 2/27/2013S&P Equity ResearchUpgradeHold -> BuyView 1/25/2013BMO Capital MarketsBoost Price TargetMarket Perform$48.00View 1/25/2013Jefferies GroupReiterated RatingHold$35.00 -> $42.00View 1/25/2013Bank of AmericaDowngradeBuy -> NeutralView 1/25/2013MizuhoBoost Price TargetNeutral$41.00 -> $45.00View 11/5/2012Canaccord GenuityReiterated RatingHoldView 10/29/2012Jefferies GroupBoost Price TargetHold$34.00 -> $35.00View 10/26/2012Canaccord GenuityReiterated RatingHold -> Hold$40.00View 10/26/2012Credit SuisseDowngradeOutperform -> NeutralView 10/22/2012MizuhoBoost Price TargetNeutral$33.00 -> $39.00View 10/4/2012UBS AGDowngradeBuy -> NeutralView 8/7/2012Commonwealth BankUpgradeHold -> BuyView 8/6/2012Feltl & Co.Boost Price TargetHold$35.75 -> $40.00View 8/6/2012Credit SuisseUpgradeNeutral -> OutperformView 8/3/2012Canaccord GenuityReiterated RatingHoldView 8/1/2012Morgan StanleyBoost Price TargetOverweight$32.95 -> $33.37View 7/19/2012Feltl & Co.DowngradeBuy -> Hold$38.00 -> $35.75View 6/25/2012Canaccord GenuityReiterated RatingHoldView 4/29/2012Bank of AmericaDowngradeBuy -> NeutralView 4/29/2012JPMorgan Chase & Co.UpgradeNeutral -> OverweightView 4/27/2012Goldman SachsUpgradeNeutral -> BuyView 4/27/2012Canaccord GenuityReiterated RatingHoldView 4/27/2012Credit SuisseDowngradeOutperform -> NeutralView 4/27/2012Feltl & Co.UpgradeHold -> Buy$38.00View 4/27/2012MizuhoBoost Price TargetNeutral$28.00 -> $32.00View 3/28/2012Feltl & Co.DowngradeBuy -> HoldView (Data available from 3/11/2012 forward) Earnings History for ResMed (NYSE:RMD)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare1/23/2014Q214$0.63$0.60$398.09 million$384.30 millionViewListenView 10/24/2013Q114$0.58$0.56$372.28 million$357.66 millionViewListenView 8/1/2013Q4 2013$0.62$0.62$410.89 million$414.60 millionViewListenView 4/25/2013Q3 2013$0.58$0.58$386.76 million$383.60 millionViewListenView 1/24/2013Q2 2013$0.51$0.53$363.76 million$376.50 millionViewListenView 10/25/2012$0.46$0.49ViewN/AView 8/2/2012$0.49$0.53ViewN/AView 4/26/2012$0.41$0.44ViewN/AView 1/26/2012$0.38$0.42ViewN/AView 10/24/2011$0.35$0.33ViewN/AView 8/4/2011$0.37$0.37ViewN/AView 4/28/2011$0.35$0.35ViewN/AView 1/27/2011$0.36$0.37ViewN/AView (Data available from 1/1/2011 forward) Dividend History for ResMed (NYSE:RMD)AnnouncedPeriodAmountEx-Dividend DateRecord DatePayable DateShare1/24/2014quarterly$0.252/14/20142/19/20143/19/2014 10/25/2013quarterly$0.2511/15/201311/19/201312/18/2013 8/2/2013quarterly$0.258/16/20138/20/20139/17/2013 4/29/2013quarterly$0.175/17/20135/21/20136/18/2013 1/25/2013quarterly$0.172/14/20132/19/20133/19/2013 (Data available from 1/1/2013 forward) Insider Trading History for ResMed (NYSE:RMD)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare2/12/2014Brett SandercockCFOSell10,687$46.00$491,602.00View 1/9/2014Peter FarrellDirectorSell25,000$48.00$1,200,000.00View 12/2/2013Robert Andrew DouglasCOOSell8,000$49.10$392,800.00View 11/20/2013Brett SandercockCFOSell15,000$51.06$765,900.00View 11/20/2013James HollingsheadInsiderSell4,000$51.24$204,960.00View 11/12/2013Donald DarkinInsiderSell31,063$50.04$1,554,392.52View 10/29/2013David PendarvisInsiderSell37,744$50.42$1,903,052.48View 10/1/2013Peter C FarrellDirectorSell25,000$53.21$1,330,250.00View 10/1/2013Robert Andrew DouglasCOOSell8,000$53.20$425,600.00View 9/9/2013Gary W PaceDirectorSell12,000$50.05$600,600.00View 9/5/2013Peter C FarrellDirectorSell25,000$48.00$1,200,000.00View 9/3/2013Robert Andrew DouglasCOOSell8,000$47.51$380,080.00View 8/28/2013Michael QuinnDirectorSell48,000$48.34$2,320,320.00View 8/27/2013Brett SandercockCFOSell5,000$49.00$245,000.00View 8/26/2013Christopher RobertsDirectorSell10,000$49.49$494,900.00View 8/1/2013Robert Andrew DouglasCOOSell8,000$48.57$388,560.00View 6/3/2013Robert Andrew DouglasCOOSell8,000$47.96$383,680.00View 5/24/2013Christopher G RobertsDirectorSell20,000$49.45$989,000.00View 5/22/2013John P WarehamDirectorSell18,000$50.20$903,600.00View 5/13/2013Michael A QuinnDirectorSell15,000$50.94$764,100.00View 5/8/2013Brett SandercockCFOSell28,000$48.97$1,371,160.00View 2/4/2013Robert Andrew DouglasCOOSell8,000$44.14$353,120.00View 8/8/2012Michael J FarrellInsiderSell30,000$35.58$1,067,400.00View (Data available from 1/1/2013 forward) About ResMed ResMed Inc., (ResMed) is a holding company for the ResMed Group. The Company, through its subsidiaries, is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing (SDB) includes obstructive sleep apnea (OSA), and other respiratory disorders that occur during sleep. The Company has developed a number of products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Its manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Its distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. In December 2013, ResMed Inc acquired Unimedis SRO, a surgical appliance and manufacturing company. Headlines: (3/10) ResMed Inc (RMD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report (3/10) First Time in its 25-year History, ResMed Unveils a New Brand, Reflecting Commitment to Changing Lives (3/3) RDInvesting Provides Investors with Free In-Depth Equity Reports on MDVN, MELI, RMD and WLK (3/5) Australian Market Recovers After Weak Start (2/25) Which are the best healthcare stocks to buy now? (2/27) Stock-up your portfolio with these top investment ideas (2/26) Australian Market Trades Weak (2/27) Asian Markets Exhibit Mixed Trend Industry, Sector and Symbol: Sector: Healthcare Industry: Health Care Equipment & Supplies Sub-Industry: Health Care Equipment Exchange: NYSE Symbol: RMD CUSIP: 76115210 Key Metrics: Previous Close: $44.2150 Day Moving Average: $44.6997200 Day Moving Average: $48.895 P/E Ratio: 19.83P/E Growth: 1.13Market Cap: $6.308BCurrent Quarter EPS Consensus Estimate: $2.53 EPS Additional Links: View RMD on Google FinanceView RMD on Yahoo FinanceView RMD's Company Profile on ReutersSearch for ResMed Inc. on Google ResMed (NYSE:RMD) Chart for Tuesday, March, 11, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.